Enveric Biosciences and University of Calgary Collaborate on a Groundbreaking Clinical Trial for EVM-101 in Cancer Related Distress
Retrieved on:
Thursday, February 17, 2022
NASDAQ, Cumming School of Medicine, Psychotherapy, Collection, Patient, Cancer, CRD, Department, Company, Prevalence, Education, Brain, SEC, Phrase, IMPACT, Forward-looking statement, U.S. Securities and Exchange Commission, University of Calgary Faculty of Law, Security (finance), DOI, Budget, University, Clinical trial, CQD, 2009–10 Calgary Flames season, Health Canada, Anxiety, Demoralization, Annual report, Intention, Calgary Flames, Institute, Mental health, Peter L. Berger, Distress, Disorder, Grammatical mood, Mood disorder, PTSD, Marketing, Hotchkiss, Disease, The Company, Research, Coronavirus, HBI, Nature, COVID-19, Program, Pharmacotherapy, Drug development, Pharmaceutical industry, Medical device, Risk management, Medicine
Approximately 50% of cancer patients report clinical levels of psychological distress having depressed mood, anxiety, demoralization, stress-induced clinical manifestations, and reduced quality of life1.
Key Points:
- Approximately 50% of cancer patients report clinical levels of psychological distress having depressed mood, anxiety, demoralization, stress-induced clinical manifestations, and reduced quality of life1.
- Up to 40% of cancer patients meet the criteria for a mood disorder requiring treatment2.
- The EVM-101 study will directly assess the core features of CRD that are most affected and amenable to improvement following a psilocybin-based treatment.
- Patient enrollment in the clinical trial is expected to begin late in 2022 or early in 2023.